VASCADE MVP^®

Ordering Information   |   AMBULATE Trial 

The AMBULATE Clinical Studies have demonstrated 0% major complications* in >1,000 patients studied in 5 EP clinical trials, including 3 trials studying same day discharge in paroxysmal and persistent AF ablation patients.^3-5

The impact of early ambulation using the VASCADE MVP^® system is that every stakeholder has the potential to accomplish their specific goals and objectives. Potential goals could be same day discharge, patient satisfaction, opioid reduction, urinary catheter reduction, greater throughput, managing limited bed space and lowering overall costs.

Ordering Information   |   AMBULATE Trial 

The VASCADE MVP^® system is FDA approved for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 6-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs⁶ and is the only extravascular closure device to offer collagen with a dual method of action, mechanical and physiological.⁹ Using a single operator, the VASCADE MVP system is simple and easy to use and leaves no sutures or other materials left behind in the vessel. The resorbable thrombogenic plug expands by 13X to fill the tissue tract.^† The VASCADE MVP system allows for re-access, after 30 days, for repeat ablation procedures.
 

Ordering Information   |   AMBULATE Trial 

VASCADE MVP^® venous vascular closure system has been proven in the prospective, multicenter randomized AMBULATE Clinical Trial,¹ demonstrating a 3.9 hour (64%) reduction in median time to ambulation as well a 63% improvement in patient satisfaction and a 58% reduction in opioid use post ablation, when compared to manual compression. The VASCADE MVP system has also demonstrated same day discharge success in the prospective multicenter AMBULATE Same Day Discharge Clinical Studies,^{4, 5} where 91.2% of patients were sent home the same day using the VASCADE MVP system.^4,5 In addition, 99.7% of VASCADE MVP same day discharge patients had no intervention during follow up⁷ and there were zero (0%) major complications.⁸

Ordering Information

Because Haemonetics^® is so committed and confident in VASCADE MVP’s ability to safely and rapidly achieve hemostasis, we offer a unique value-based purchasing program called the VASCADE MVP^® Performance Guarantee. In the event of a qualified complication as the result of VASCADE MVP, Haemonetics will provide financial reimbursement to your hospital or practice. It’s simple, we’re dedicated to exceptional outcomes for you and your patients. We stand behind our products based on proven safety and efficacy published in peer-reviewed clinical studies.